Oncor
This article was originally published in The Gray Sheet
Executive Summary
Submits premarket approval application Oct. 3 for the in vitro diagnostic use of its chronic myelogenous leukemia (CML) Mbcr/abl genetic test system. The company says that in multi-center trials involving close to 350 patients, the Oncor test, when used alone, "was 96.1% sensitive and 99.3% specific in detecting CML, compared to the detection rates of a combination of the best presently available methods." The Gaithersburg, Maryland-based firm estimates that its test will cost "five times less than conventional methods"
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.